Chris Kay Bloomberg

Bollywood has a serious rival now in India. It's bigger, louder and is making more money than its prolific, glitzy Hindi-language cousin known for its signature dance moves and opulent wedding scenes.

Treatment-resistant typhoid originating mostly from South Asia has springboarded across borders almost 200 times in the past three decades, according to new research that underscores the rising global threat of infections that can evade antibiotics.

Tata Consumer Products Ltd., the food and beverage arm of the $103 billion Indian conglomerate, wants to go on an acquisition spree to bolster its position in the country's competitive consumer goods sector.

Asia's two richest men -- Gautam Adani and Mukesh Ambani -- are doubling down on India's media sector, intensifying competition in an arena where Netflix Inc. and Amazon.com Inc. are also vying for more than a billion viewers.

On the edge of Hyderabad in southern India, a vast patch of arid shrub-land the size of about 14,000 football fields is becoming a testing ground for a model that could help wean the world off its dependence on Chinese drug ingredients.

Britannia Industries Ltd., Indias biggest cookie manufacturer, plans to hike prices as much as 7% this year in another sign that inflationary pressures will hurt poorer consumers the most, as the war in Ukraine wreaks havoc on food supply chains.

Amazon.com Inc. and Netflix Inc. are among platforms partnering with Indian production house Clean Slate Filmz Pvt. to push out movies and web series worth about 4 billion rupees ($54 million) as the battle for content heats up in one of the world's

The government faces a growing clamor from business leaders and public health experts to launch a Covid-19 booster drive and begin vaccinating children as the nation braces for a surge of omicron-fueled infections.

The omicron variant infects around 70 times faster than delta and the original Covid-19 strain, though the severity of illness is likely to be much lower, according to a University of Hong Kong study.

India vaulted 19 spots in Bloomberg's Covid Resilience Ranking of the best and worst places to be amid the pandemic, marking a turnaround for a country that saw the world's fastest-growing Covid outbreak earlier this year.

India will bolster Covid-19 genome sequencing efforts, hoping early detection of the newly-emerged omicron variant will help avoid a repeat of the Delta-fueled wave of infections that brought its health system close to collapse earlier this year.

Covaxin, one of the main vaccines used in India's coronavirus immunization drive, provides only 50% protection against symptomatic COVID-19, according to a real-world study that suggests the shot is less effective than initially thought.

Four years after ceasing sales in India, General Motors remains mired in legal challenges from the labor union that represents more than 1,000 former workers that the company let go from the plant, effectively barring its exit.

For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.

Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.

Bollywood has a serious rival now in India. It's bigger, louder and is making more money than its prolific, glitzy Hindi-language cousin known for its signature dance moves and opulent wedding scenes.

Treatment-resistant typhoid originating mostly from South Asia has springboarded across borders almost 200 times in the past three decades, according to new research that underscores the rising global threat of infections that can evade antibiotics.

Tata Consumer Products Ltd., the food and beverage arm of the $103 billion Indian conglomerate, wants to go on an acquisition spree to bolster its position in the country's competitive consumer goods sector.

Asia's two richest men -- Gautam Adani and Mukesh Ambani -- are doubling down on India's media sector, intensifying competition in an arena where Netflix Inc. and Amazon.com Inc. are also vying for more than a billion viewers.

On the edge of Hyderabad in southern India, a vast patch of arid shrub-land the size of about 14,000 football fields is becoming a testing ground for a model that could help wean the world off its dependence on Chinese drug ingredients.

Britannia Industries Ltd., Indias biggest cookie manufacturer, plans to hike prices as much as 7% this year in another sign that inflationary pressures will hurt poorer consumers the most, as the war in Ukraine wreaks havoc on food supply chains.

Amazon.com Inc. and Netflix Inc. are among platforms partnering with Indian production house Clean Slate Filmz Pvt. to push out movies and web series worth about 4 billion rupees ($54 million) as the battle for content heats up in one of the world's

The government faces a growing clamor from business leaders and public health experts to launch a Covid-19 booster drive and begin vaccinating children as the nation braces for a surge of omicron-fueled infections.

The omicron variant infects around 70 times faster than delta and the original Covid-19 strain, though the severity of illness is likely to be much lower, according to a University of Hong Kong study.

India vaulted 19 spots in Bloomberg's Covid Resilience Ranking of the best and worst places to be amid the pandemic, marking a turnaround for a country that saw the world's fastest-growing Covid outbreak earlier this year.

India will bolster Covid-19 genome sequencing efforts, hoping early detection of the newly-emerged omicron variant will help avoid a repeat of the Delta-fueled wave of infections that brought its health system close to collapse earlier this year.

Covaxin, one of the main vaccines used in India's coronavirus immunization drive, provides only 50% protection against symptomatic COVID-19, according to a real-world study that suggests the shot is less effective than initially thought.

Four years after ceasing sales in India, General Motors remains mired in legal challenges from the labor union that represents more than 1,000 former workers that the company let go from the plant, effectively barring its exit.

For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.

Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.